Tacrolimus is used as an immunosuppressant mainly after organ
transplant procedures to prevent organ rejection. Tacrolimus inhibits
the activation of serine-threonine phosphatase, calcineurin, in T
lymphocytes. This suppresses T lymphocyte activation and the
subsequent generation of cytotoxic lymphocytes, thereby suppressing
processes leading to organ rejection. Tacrolimus is primary
immunosuppression drug used in kidney and liver transplant patients.
Organ transplanted patients often require lifelong treatment with
immunosuppressant. Major applications of this includes in cardiac
transplant rejection, liver transplant rejection, kidney transplant
rejection, and lung transplant immunosuppression treatment.
Tacrolimus is available in various dosage forms such as tablets,
capsules, and injections.
Download
PDF Brochure @
https://www.coherentmarketinsights.com/insight/request-pdf/2298
Tacrolimus Market Drivers
Tacrolimus is majorly used as an immunosuppressant after organ
transplant procedures. Advancement in organ transplant procedures is
a major factor expected to increase the number of organ transplants,
which in turn is expected to boost global tacrolimus market growth
over the forecast period. For instance, new methods are being
researched to match more donor organs with patients such as stem cell
studies, trophic factor studies, and natural models. As the need for
organ transplantation increases and the waiting list continues to
grow, successful utilization and transplantation of as many available
donor organs as possible has become important. According to Organ
Procurement and Transplantation Network (OPTN) 117,000+ number of
men, women, and children are on the national transplant waiting list
as of July 2017 in the U.S. and 17,155 organ transplants are done so
far in 2017.
Tacrolimus Market Regional Analysis
North America tacrolimus market is expected to dominate over the
forecast period. Presence of leading manufacturers as well as high
number of organ transplant procedures is expected to support global
tacrolimus market growth. Regional generic manufacturers are focusing
on providing generic version of tacrolimus formulations in developed
as well emerging economies. For instance, Strides Arcolab received
the U.S. Food & Drug Administration (FDA) approval for tacrolimus
capsules to be used as immuno-suppressant in 2014. Sandoz launched
Tacrolimus, a generic version of Astellas’s PROGRAF (tacrolimus) in
Japan, in 2015. Moreover, The European Medicines Agency’s (EMA)
Committee for Medicinal Products for Human Use (CHMP) recommended
granting marketing authorization for tacrolimus’ generic, Tacforius
in 2017. These factors have supported the global tacrolimus market
growth.
Tacrolimus Market Key Players
Key players operating in the global tacrolimus market include
GlaxoSmithKline Plc, Abbott Laboratories, Novartis International AG,
Mylan N.V., Astellas Pharma, Inc., Takeda Pharmaceuticals Company
Ltd, Senju Pharmaceutical Co. Ltd., Guike Pharmaceutical Co. Ltd.,
DR. Reddy’s Laboratories Ltd., and Glenmark Pharmaceuticals Ltd.
Tacrolimus Market Taxonomy:
The global tacrolimus market is segmented on the basis of product
type, application, end user, and region
By Product Type:
-
Tacrolimus Capsules and Tablets
-
Tacrolimus Ointment
-
Tacrolimus Injection
By Application:
-
Immunosuppression
-
Dermatitis
-
Others
Browse
Research Report @
https://www.coherentmarketinsights.com/ongoing-insight/tacrolimus-market-2298
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and
consulting firm offering action-ready syndicated research reports,
custom market analysis, consulting services, and competitive analysis
through various recommendations related to emerging market trends,
technologies, and potential absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
No comments:
Post a Comment